BMRN Q1 2024 Earnings — BioMarin Pharmaceutical Inc. Revenue & Financial Results | Market Cap Arena

BMRNBioMarin Pharmaceutical Inc.

$12B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$649M+8.8% YoY

Gross Profit

$524M80.7% margin

Operating Income

$88M13.6% margin

Net Income

$89M13.7% margin

EPS (Diluted)

$0.46

QoQ Revenue Growth

+0.4%

Cash Flow

Operating Cash Flow

$47M

Free Cash Flow

$13M

Stock-Based Comp.

$58M

Balance Sheet

Total Assets

$6.9B

Total Liabilities

$1.8B

Stockholders' Equity

$5.1B

Cash & Equivalents

$747M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$649M	$596M	+8.8%
Gross Profit	$524M	$461M	+13.6%
Operating Income	$88M	$62M	+41.8%
Net Income	$89M	$51M	+74.4%

Revenue Segments

Product

$638M98%

Royalty And Other

$11M2%